A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies
A Phase 1, Multicenter, Open-label Study to Evaluate the Pharmacokinetics of CC-486 (Onureg®) in Subjects With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Adult Subjects With Myeloid Malignancies
Sponsor: Bristol-Myers Squibb
Terminated
Insufficient Enrollment
Other terminated trials from Bristol-Myers Squibb
Other Hepatic Insufficiency trials with similar outcome
Listed as NCT05209295, this PHASE1 trial focuses on Hepatic Insufficiency and Neoplasms and remains terminated or withdrawn. Sponsored by Bristol-Myers Squibb, it has been updated 17 times since 2024, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
17 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Jul 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Dec 2024 — Jul 2025 [monthly]
Recruiting PHASE1
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE1
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE1
▶ Show 12 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE1
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE1
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE1
-
Dec 2023 — Feb 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Nov 2023 — Dec 2023 [monthly]
Not Yet Recruiting PHASE1
-
Sep 2023 — Nov 2023 [monthly]
Not Yet Recruiting PHASE1
-
Aug 2023 — Sep 2023 [monthly]
Not Yet Recruiting PHASE1
-
Jun 2023 — Aug 2023 [monthly]
Not Yet Recruiting PHASE1
-
May 2023 — Jun 2023 [monthly]
Not Yet Recruiting PHASE1
-
Feb 2022 — May 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
For direct contact, visit the study record on ClinicalTrials.gov .